Why Pharma Manufacturing Can't Adopt Automation Like Other Industries

Pharmaceutical manufacturers are investing heavily in automation to address workforce shortages and supply chain disruption, but they face constraints that don't apply to most other industries.

Unlike discrete manufacturing environments where companies can deploy new technology and optimize it through iterative refinement, pharmaceutical operations must validate every process change before implementation. This validation demonstrates that modifications consistently meet quality standards and regulatory requirements, with patient safety as the non-negotiable priority.

The validation burden makes pharmaceutical companies inherently more cautious about adopting new automation technologies. Each change requires documentation, testing, and regulatory review before it can touch production.

Why it matters

As labor shortages intensify and supply chains remain volatile, pharmaceutical companies cannot afford to fall behind on automation. Understanding the industry's unique constraints helps technology vendors design solutions that account for validation requirements from the start, rather than treating compliance as an afterthought. It also explains why pharma automation projects often have longer timelines and higher upfront costs than comparable manufacturing initiatives.

Acceleration despite constraints

Despite these hurdles, automation investment in life sciences is accelerating rather than slowing. Multiple pressures are converging: workforce shortages, supply chain disruption, reshoring initiatives, and increasing demand for medicines.

Companies are exploring automated material handling, advanced planning systems, digital twins, and predictive analytics. The goal is improving operational agility while maintaining the compliance posture regulators demand.

Strategic selectivity required

The validation requirement means pharmaceutical manufacturers must be more selective about which processes to automate. Not every automation opportunity makes sense when weighed against implementation complexity and regulatory risk.

Cleanroom requirements, validated sanitation procedures, and manual quality activities often require careful evaluation before automation. Organizations should identify where automation delivers meaningful operational value without introducing unnecessary complexity.

The decision framework differs from other industries where the calculation is simpler: if automation improves throughput or reduces cost, deploy it.

Building resilient operations

According to Cate Davis, global lead for pharma and life sciences at Miebach Consulting North America, the industry should view automation as part of a broader operational strategy rather than an effort to match the pace of other sectors.

The objective is building manufacturing operations that are resilient, flexible, and capable of responding to changing products, evolving demands, and increasingly complex supply chains—all while continuing to meet the industry's quality standards.

This perspective reframes automation as a strategic capability rather than a tactical technology deployment. It acknowledges that pharmaceutical manufacturing operates under different rules and requires a different approach.

These insights were originally reported by Automation World in an article by Davis published in August 2026.